Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment - ISAR-REACT 2


The goal of the trial was to evaluate the efficacy of treatment with the glycoprotein (GP) IIb/IIIa inhibitor abciximab compared with placebo among patients undergoing percutaneous coronary intervention (PCI) for a non-ST-segment elevation acute coronary syndrome (ACS) who were treated with high-dose (600 mg) clopidogrel.